JP2003189887A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003189887A5 JP2003189887A5 JP2002327364A JP2002327364A JP2003189887A5 JP 2003189887 A5 JP2003189887 A5 JP 2003189887A5 JP 2002327364 A JP2002327364 A JP 2002327364A JP 2002327364 A JP2002327364 A JP 2002327364A JP 2003189887 A5 JP2003189887 A5 JP 2003189887A5
- Authority
- JP
- Japan
- Prior art keywords
- gene
- vector
- human
- chimeric construct
- expression cassette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000013598 vector Substances 0.000 claims 12
- 230000014509 gene expression Effects 0.000 claims 11
- 239000002245 particle Substances 0.000 claims 10
- 108090000623 proteins and genes Proteins 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 239000003623 enhancer Substances 0.000 claims 7
- 230000003612 virological effect Effects 0.000 claims 7
- 108010085238 Actins Proteins 0.000 claims 5
- 241000700605 Viruses Species 0.000 claims 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims 4
- 210000002027 skeletal muscle Anatomy 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 210000003205 muscle Anatomy 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 239000013603 viral vector Substances 0.000 claims 3
- 108010042126 Creatine kinase Proteins 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 2
- 101000877537 Homo sapiens Beta-enolase Proteins 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 206010034576 Peripheral ischaemia Diseases 0.000 claims 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 claims 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 claims 2
- 238000001415 gene therapy Methods 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000002363 skeletal muscle cell Anatomy 0.000 claims 2
- 108700026220 vif Genes Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 102000004420 Creatine Kinase Human genes 0.000 claims 1
- 241000701022 Cytomegalovirus Species 0.000 claims 1
- 241000714192 Human spumaretrovirus Species 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000710961 Semliki Forest virus Species 0.000 claims 1
- 108090001027 Troponin Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000006806 disease prevention Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 230000001023 pro-angiogenic effect Effects 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01440378 | 2001-11-09 | ||
| EP01440378.6 | 2001-11-09 | ||
| US33176701P | 2001-11-21 | 2001-11-21 | |
| US60/331767 | 2001-11-21 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003189887A JP2003189887A (ja) | 2003-07-08 |
| JP2003189887A5 true JP2003189887A5 (2) | 2005-10-13 |
Family
ID=26077288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002327364A Withdrawn JP2003189887A (ja) | 2001-11-09 | 2002-11-11 | 筋肉細胞での発現を制御するためのキメラプロモーター |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20030157064A1 (2) |
| JP (1) | JP2003189887A (2) |
| CA (1) | CA2406687A1 (2) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11541131B2 (en) | 2017-03-10 | 2023-01-03 | Genethon | Treatment of glycogen storage disease III |
| EP3749771A1 (en) | 2018-02-07 | 2020-12-16 | Genethon | Hybrid regulatory elements |
| CA3107572A1 (en) | 2018-08-08 | 2020-02-13 | Genethon | Mini-gde for the treatment of glycogen storage disease iii |
| BR112021020888A2 (pt) | 2019-04-19 | 2021-12-21 | Genethon | Terapia gênica de doenças hipofosfatêmicas relacionadas a fator de crescimento fibroblástico 23 |
| EP4179096A1 (en) * | 2020-07-10 | 2023-05-17 | Genethon | A novel muscle-specific promoter |
| US20230313152A1 (en) | 2020-08-24 | 2023-10-05 | Genethon | C-terminal truncated gde for the treatment of glycogen storage disease iii |
| CN113106094B (zh) * | 2021-04-07 | 2022-10-18 | 四川大学 | 增强型骨骼肌细胞高效特异性启动子、筛选方法及应用 |
| AU2022260111A1 (en) | 2021-04-20 | 2023-11-30 | Anjarium Biosciences Ag | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| JP2025504404A (ja) | 2022-01-14 | 2025-02-12 | アンジャリウム バイオサイエンシズ エージー | Ｖｉｉｉ因子をコードするｄｎａ分子の組成物、それを作製する方法、及びその使用方法 |
| CN114231532B (zh) * | 2022-02-22 | 2022-06-17 | 广州派真生物技术有限公司 | 在哺乳动物肌肉中特异性启动基因的启动子序列及其应用 |
| JP2025524363A (ja) | 2022-06-09 | 2025-07-30 | ジェネトン | 糖原病ｉｉｉの処置のためのｎ末端短縮型ｇｄｅ |
| EP4677073A1 (en) | 2023-03-10 | 2026-01-14 | Genethon | Induction of immune tolerance by aav vector comprising the combination of a liver detargeted capsid and a tandem liver-muscle specific promoter |
| CN121420060A (zh) | 2023-06-29 | 2026-01-27 | 吉尼松公司 | 用于治疗糖原贮积病iii的n-端截短的糖原脱支酶 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU745409B2 (en) * | 1997-01-29 | 2002-03-21 | Cornell Research Foundation Inc. | Multiple site delivery of adenoviral vector for the induction of angiogenesis |
| CA2419245A1 (en) * | 2000-08-17 | 2002-02-21 | Keiya Ozawa | Adeno-associated virus-mediated delivery of angiogenic factors |
| ATE400656T1 (de) * | 2000-10-06 | 2008-07-15 | Univ Michigan | Mini-dystrophin nukleinsäure- und peptidsequenzen |
| EP2017338A1 (en) * | 2001-05-24 | 2009-01-21 | Genzyme Corporation | Muscle-specific expression vectors |
-
2002
- 2002-11-08 CA CA002406687A patent/CA2406687A1/en not_active Abandoned
- 2002-11-08 US US10/290,327 patent/US20030157064A1/en not_active Abandoned
- 2002-11-11 JP JP2002327364A patent/JP2003189887A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Santoro et al. | NF‐κB and virus infection: who controls whom | |
| TWI704226B (zh) | 重組溶瘤病毒組合物及其用途 | |
| JP2003189887A5 (2) | ||
| Brenner et al. | Current developments in the design of onco-retrovirus and lentivirus vector systems for hematopoietic cell gene therapy | |
| JP6193120B2 (ja) | 組換え腫瘍ワクチンおよびこのようなワクチンを生産する方法 | |
| JP2009508471A5 (2) | ||
| JP2005505286A5 (2) | ||
| CN109641064A (zh) | 非整合病毒递送系统及其相关方法 | |
| WO1995026411A3 (en) | Composition and methods for creating syngeneic recombinant virus-producing cells | |
| WO2003047617A3 (en) | Vaccine | |
| KR102173189B1 (ko) | 아데노 바이러스 생산 세포주 및 이의 제조방법 | |
| JP2004501650A5 (2) | ||
| JP2003503355A5 (2) | ||
| CA2478616A1 (en) | Use of adenoviruses mutated in the va genes for cancer treatment | |
| JP2007522797A5 (2) | ||
| Jane et al. | Vector development: a major obstacle in human gene therapy | |
| ES2320157T3 (es) | Kit de partes diseñado para poner en practica un tratamiento atitumoral o antivirico en un mamifero. | |
| Berlinghoff et al. | Susceptibility of mesothelioma cell lines to adeno-associated virus 2 vector-based suicide gene therapy | |
| JP2020535203A5 (2) | ||
| KR20030047819A (ko) | 인터루킨-18 단백질을 발현하는 재조합 아데노바이러스 및그를 이용한 유전자치료 | |
| CA2466889A1 (en) | Use of the adenoviral e2 late promoter | |
| AU2003225141A1 (en) | Alternatively spliced nucleic acid molecules | |
| JP2020536519A5 (2) | ||
| KR100342382B1 (ko) | 간암 특이적 세포 살상 재조합 아데노바이러스 | |
| JP2002535961A5 (2) |